Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Cytokinetics, Incorporated (CYTK), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
-8.72
P/B ratioShare price divided by book value per share.
-47.86
P/S ratioMarket value divided by annual revenue.
123.15
PEG ratioP/E divided by the earnings growth rate.
0.26
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.
-11.87
EV / RevenueEnterprise value against annual revenue.
137.46
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-11.36%
Free cash flow yieldFree cash flow as a percentage of market value.
-6.65%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
84.97%
Operating marginRevenue left after operating costs.
-992.98%
Net marginRevenue left after every cost, including tax and interest.
-784.02%
Return on equityProfit as a percentage of shareholders’ equity.
163.98%
Return on assetsProfit as a percentage of total assets.
-46.45%
Return on capital employedOperating profit against the capital the business uses.
-40.42%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
6.66
Quick ratioThe same, excluding inventory.
6.66
Cash ratioCash alone against current liabilities.
0.61
Debt to equityTotal borrowings against shareholders’ equity.
-7.32
Debt to assetsTotal borrowings against total assets.
0.90
Interest coverageHow many times operating profit covers the interest bill.
-5.64
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
$-6.54
Book value per shareShareholders’ equity divided by shares outstanding.
$0.00
Shares outstandingShares currently issued.
0
Market capitalisationShare price times shares outstanding.
$8.51B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$9.75B
EmployeesReported headcount.
673
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
Cytokinetics, Incorporated (CYTK) trades on a price-to-earnings ratio of -8.72. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.
What is Cytokinetics, Incorporated's return on equity?
Cytokinetics, Incorporated (CYTK) reports a return on equity of 163.98%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does Cytokinetics, Incorporated carry?
Cytokinetics, Incorporated (CYTK) has a debt-to-equity ratio of -7.32, which compares total borrowings with shareholders' equity.
What is Cytokinetics, Incorporated's profit margin?
Cytokinetics, Incorporated (CYTK) keeps -784.02% of revenue as net profit after every cost, including tax and interest.